Physician profile
Robert Snitzer
NPI 1225037252
$2,324.71
in general payments reported to CMS, 2019-2025
22 companies · $421 in 2025
The $421 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.86 · 2020: $225 · 2021: $145 · 2022: $421 · 2023: $437 · 2024: $578 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,404 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,404.20 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $668.49 | 2019-2024 | Watchman Access System |
| Abbott Laboratories | $460.33 | 2022-2025 | Merlin@Home, Assurity, Jot Dx |
| Novartis Pharmaceuticals Corporation | $265.54 | 2022-2025 | |
| Pfizer INC. | $186.89 | 2022-2025 | |
| Amgen INC. | $102.23 | 2019-2024 | Repatha |
| Sanofi-Aventis U.S. LLC | $86.74 | 2023-2024 | |
| Kestra Medical Technology Services, INC. | $73.30 | 2024-2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $61.14 | 2021-2025 | Lifevest |
| Esperion Therapeutics, INC. | $60.77 | 2023-2025 | Nexletol |
| Kiniksa Pharmaceuticals, LTD. | $47.55 | 2022-2023 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $45.85 | 2021-2024 | |
| Medtronic, INC. | $41.52 | 2022-2023 | Linq II |
| Cvrx, INC. | $34.24 | 2025 | Barostim Neo System |
| Novo Nordisk INC | $32.27 | 2025 | Ozempic |
| Merck Sharp & Dohme LLC | $30.07 | 2022-2023 | Verquvo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $27.23 | 2024 | Optimizer |
| Exact Sciences Corporation | $21.21 | 2025 | Cologuard Collection Kit |
| Kiniksa Pharmaceuticals International, Plc | $20.00 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $19.97 | 2025 | Camzyos |
| Chiesi USA, INC. | $17.80 | 2022 | |
| Abiomed | $13.96 | 2024 | Impella |
| Cardiovascular Systems INC. | $7.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Snitzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.